Switching to an Infliximab Biosimilar Was Safe and Effective in Dutch Sarcoidosis Patients
The effect of switching from originator infliximab to biosimilar infliximab in patients with sarcoidosis is unknown. The objective of this study is to investigate the effect of switching from Remicade<sup>®</sup> or Inflectra<sup>®</sup> to Flixabi<sup>®</sup> in patients with severe refractory sarc...
Uloženo v:
| Hlavní autoři: | , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
MDPI AG
2021-02-01
|
| Edice: | Cells |
| Témata: | |
| On-line přístup: | https://www.mdpi.com/2073-4409/10/2/441 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|